Skip to main content
Premium Trial:

Request an Annual Quote

The Data is Already Out There

The Business Bytes Genes Molecules blog's Deepak Singh says it may be time to put away the microarray gene expression experiments and pay attention to the data that's already been gathered by other researchers to get more focused on "useful science." Singh, who references Atul Butte's talk at the Sage Congress on publicly available data, says there will soon be sufficient public data available for "smart people ... to do a lot of interesting things, such as identifying data-driven candidate genes." The key lessons Butte presented, Singh says, are: sufficient data already exists to impact medicine, public molecular data is of high quality, imperfect annotations are still very useful, researchers should focus on using the tools they really need, and that students need to be trained to use data to "initiate science."

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.